First trial of faecal microbiota transplantation for people with active peripheral psoriatic arthritis shows no advantage
In this proof-of-concept study, Maja Skov Kragsnaes and colleagues evaluated efficacy and safety of FMT in people with psoriatic arthritis (PsA). PsA is an inflammatory arthritis that causes a person’s joints to become stiff and painful. It is often found people with the skin condition psoriasis, and there is also a link between PsA and inflammatory bowel disease or gastrointestinal symptoms.
This double-blind, parallel-group, sham-controlled, superiority trial randomly allocated31adults with active peripheral PsAd espite ongoing treatment with methotrexate to one gastroscopic-guided FMT procedure, or sham transplantation into the duodenum. The transplants (50 g faeces) came from one of four healthy, anonymous stool donors. The primary efficacy endpoint was the proportion of participants experiencing treatment failure, defined as needing treatment intensification through 26 weeks, and safety was monitored throughout.
The results showed that treatment failure occurred more frequently in the FMT group than in the sham group (60%versus19%, and improvement in function was also in favour of sham. No serious adverse events were observed.